The synergistic killing of AML cells co-cultured with HS-5 bone marrow stromal cells by As2O3 and the PI3K/Akt signaling pathway inhibitor LY294002

Pharmazie

Volumn 70, Issue 5, 2015, Pages 322-327

  Chen, Ping ^a   Wu, Juanying ^a   Yuan, Qin ^a   Jiang, Xi ^a   Huang, Huifang ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ARSENIC TRIOXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; ANTINEOPLASTIC AGENT; CHROMONE DERIVATIVE; ENZYME INHIBITOR; MORPHOLINE DERIVATIVE; ONCOPROTEIN; ORGANOARSENIC DERIVATIVE; OXIDE;

ACUTE MYELOBLASTIC LEUKEMIA; ADHERENT CELL; APOPTOSIS; ARTICLE; BONE MARROW STROMA CELL; CANCER CELL CULTURE; CANCER RESISTANCE; CELL ADHESION; CELL CYCLE G1 PHASE; CELL KILLING; CELL PROLIFERATION; COCULTURE; DOWN REGULATION; FLOW CYTOMETRY; HL 60 CELL LINE; HUMAN; HUMAN CELL; LEUKEMIA CELL; MICROENVIRONMENT; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SUSPENSION CELL CULTURE; U937 CELL LINE; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; BONE MARROW CELL; DRUG EFFECTS; DRUG POTENTIATION; STROMA CELL; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; BONE MARROW CELLS; CELL ADHESION; CELL LINE, TUMOR; CHROMONES; COCULTURE TECHNIQUES; DRUG SYNERGISM; ENZYME INHIBITORS; HL-60 CELLS; HUMANS; MORPHOLINES; ONCOGENE PROTEIN V-AKT; OXIDES; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION; STROMAL CELLS; U937 CELLS;

EID: 84930670025     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2015.4853     Document Type: Article

References (34)

1. Becker PS, Kopecky KJ, Wilks AN, Chien S, Harlan JM, Willman CL, Petersdorf SH, Stirewalt DL, Papayannopoulou T, Appelbaum FR (2009) Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia. Blood 113: 866-874.
2. Bortul R, Tazzari PL, Billi AM, Tabellini G, Mantovani I, Cappellini A, Grafone T, Martinelli G, Conte R, Martelli AM (2005) Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway. Br J Haematol 129: 677-686.
3. Carmosino I, Latagliata R, Avvisati G, Breccia M, Finolezzi E, Lo Coco F, Petti MC (2004) Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia. Haematologica 89: 615-617.
4. Chan WI, Huntly BJ (2008) Leukemia stem cells in acute myeloid leukemia. Semin Oncol 35: 326-335.
5. Chen D, Chan R, Waxman S, JingY(2006) Buthionine sulfoximine enhancement of arsenic trioxide-induced apoptosis in leukemia and lymphoma cells is mediated via activation of c-Jun NH2-terminal kinase and upregulation of death receptors. Cancer Res 66: 11416-11423.
6. Chen F, Zhou K, Zhang L, Ma F, Chen D, Cui J, Feng X, Yang S, Chi Y, Han Z, Xue F, Rong L, Ge M, Wan L, Xu S, Du W, Lu S, Ren H, Han Z (2013) Mesenchymal stem cells induce granulocytic differentiation of acute promyelocytic leukemic cells via IL-6 and MEK/ERK pathways. Stem Cells Dev 22: 1955-1967.
7. Chen Ping, Wu Juan Y, Huang Hui F, Chen Yuan Z (2014) The effect to IL-3Rα, downstream PI3K/Akt signaling of all-trans retinoic acid and arsenic trioxide in NB4 cells. Pharmazie 69: 297-300.
8. Funayama K, Shimane M, Nomura H, Asano S (2010) An evidence for adhesion-mediated acquisition of acute myeloid leukemic stem cell-like immaturities. Biochem Biophys Res Commun 392: 271-276.
9. Goldman DC, Bailey AS, Pfaffle DL, Al Masri A, Christian JL, Fleming WH (2009) BMP4 regulates the hematopoietic stem cell niche. Blood 114: 4393-4401.
10. Guo-Bao W, Xiao-Qin C, Qi-Rong G, Jie L, Gui-Nan L, Yue L (2010) Arsenic trioxide overcomes cell adhesion-mediated drug resistance through down-regulating the expression of beta (1)-integrin in K562 chronic myelogenous leukemia cell line. Leuk Lymphoma 51: 1090-1097.
11. Huang HF, Lu R, Chen P, Lin ZX, Wu Y, Chen YZ (2012) Direct contact with bone stromal HS-5 cells reduces the sensitivity of HEL to drugs. Zhongguo Shi Yan Xue Ye Xue Za Zhi 20: 818-822.
12. Huntly BJ, Gilliland DG (2005) Leukemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer 5: 311-321.
13. Katsumi A, Kiyoi H, Abe A, Tanizaki R, Iwasaki T, Kobayashi M, Matsushita T, Kaibuchi K, Senga T, Kojima T, Kohno T, Hamaguchi M, Naoe T (2011) FLT3/ITD regulates leukaemia cell adhesion through α4β1 integrin and Pyk2 signalling. Eur J Haematol 86: 191-198.
14. Konopleva M, Konoplev S, Hu W, Zaritskey AY, Afanasiev BV, Andreeff M (2002) Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia 16: 1713-1724.
15. Krause DS, Fulzele K, Catic A, Sun CC, Dombkowski D, Hurley MP, Lezeau S, Attar E, Wu JY, Lin HY, Divieti-Pajevic P, Hasserjian RP, Schipani E, Van Etten RA, Scadden DT (2013) Differential regulation of myeloid leukemias by the bone marrow microenvironment. Nat Med 19: 1513-1517.
16. Kubota Y, Ohnishi H, Kitanaka A, Ishida T, Tanaka T (2004) Constitutive activation of PI3K is involved in the spontaneous proliferation of primary acute myeloid leukemia cells:direct evidence of PI3K activation. Leukemia 18: 1438-1440.
17. Leoni F, Gianfaldoni G, Annunziata M, Fanci R, Ciolli S, Nozzoli C, Ferrara F (2002) Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation. Haematologica 87: 485-489.
18. Li H, Koh KR, Toramoto T, Nakamae H, Yamane T, Ohta K, HinoM(2010) Cytosine- arabinoside stimulates the capability of human marrow stromal cells to support normal hematopoiesis. Osaka City Med J 56: 11-20.
19. Li Y, Chen S, Yuan J, Yang Y, Li J, Ma J, Wu X, Freund M, Pollok K, Hanenberg H, Goebel WS, Yang FC (2009) Mesenchymal stem/progenitor cells promote the reconstitution of exogenous hematopoietic stem cells in Fancg-/- mice in vivo. Blood 113: 2342-2351.
20. Longo PG, Laurenti L, Gobessi S, Sica S, Leone G, Efremov DG (2008) The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 111: 846-855.
21. Macanas-Pirard P1, Leisewitz A, Broekhuizen R, Cautivo K, Barriga FM, Leisewitz F, GidiV, Riquelme E, MontecinosVP, Swett P, Besa P, Ramirez P, Ocqueteau M, Kalergis AM, Holt M, Rettig M, DiPersio JF, Nervi B (2012) Bone marrow stromal cells modulate mouse ENT1 activity and protect leukemia cells from cytarabine induced apoptosis. PLoS One 7: e37203.
22. Martelli AM, Nyåkern M, Tabellini G, Bortul R, Tazzari PL, Evangelisti C, Cocco L (2006) Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia 20: 911-928.
23. Nemeth MJ, Mak KK, Yang Y, Bodine DM (2009) beta-Catenin expression in the bone marrow microenvironment is required for long-term maintenance of primitive hematopoietic cells. Stem Cells 27: 1109-1119.
24. Osaki M, Oshimura M. Ito H (2004) PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9: 667-676.
25. Parmar A, Marz S, Rushton S, Holzwarth C, Lind K, Kayser S, Döhner K, Peschel C, Oostendorp RA, Götze KS (2011) Stromal niche cells protect early leukemic FLT3-ITD + progenitor cells against first-generation FLT3 tyrosine kinase inhibitors.Cancer Res 71: 4696-4706.
26. Ramos AM, Fernández C, Amrán D, Sancho P, de Blas E, Aller P (2005) Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells. Blood 105: 4013-4020.
27. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA, Steinherz P, Sievers EL, Coutré S, Dahlberg S, Ellison R, Warrell RP Jr. (2001) United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19: 3852-3860.
28. Tabe Y, Jin L, Tsutsumi-Ishii Y, Xu Y, McQueen T, Priebe W, Mills GB, Ohsaka A, Nagaoka I, Andreeff M, Konopleva M (2007) Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res 67: 684-694.
29. Tabellini G, Cappellini A, Tazzari PL, Falà F, Billi AM, Manzoli L, Cocco L, Martelli AM (2005) Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells. J Cell Physiol 202: 623-634.
30. Taussig DC, Vargaftig J, Miraki-Moud F, Griessinger E, Sharrock K, Luke T, Lillington D, Oakervee H, Cavenagh J, Agrawal SG, Lister TA, Gribben JG, Bonnet D (2010) Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood 115: 1976-1984.
31. Tazzari PL, Cappellini A, Ricci F, Evangelisti C, Papa V, Grafone T, Martinelli G, Conte R, Cocco L, McCubrey JA, MartelliAM(2007) Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia 21: 427-438.
32. West KA, Castillo SS, Dennis PA(2002) Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updates 5: 234-248.
33. Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M (2003) Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 102: 972-980.
34. Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling X, Frolova O, Levis M, Rubin JB, Negrin RR, Estey EH, Konoplev S, AndreeffM, KonoplevaM(2009) Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 113: 6215-6224.